Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma

Table 2 Select studies on neoadjuvant systemic chemotherapy for intrahepatic cholangiocarcinoma

Ref.	Study type	Intervention	Sample size	Conversion to resection	Tumor response
Kato et al[46], 2013	Retrospective	Gemcitabine	22	8 (37%)	3 PR, 11 SD, 8 PD
Kato et al[47], 2015	Retrospective	Gemcitabine plus cisplatin	39	10 (26%)	9PR, 21 SD, 9 PD
Rayar et al[71], 2017	Retrospective	Gemcitabine and/or platinums; Y-90 TARE	45	10 (22%)	NR
Konstantinidis et al[79], 2017	Retrospective	Bevacizumab + FUDR HAI	104	8 (8%)	NR
Omichi et al[110], 2017	Retrospective	Gemcitabine based therapy	43	43 (100%)	NR
Le Roy et al[48], 2018	Retrospective	Gemcitabine plus oxaliplatin	74	39 (53%)	18 PR, 33 SD, 23 PD
Sumiyoshi et al[112], 2018	Retrospective	S-1 + IMRT	7	5 (71%)	4 PR, 1 SD, 2 PD

NR: Not reported; PR: Partial response; SD: Stable disease; PD: Disease progression; ICC: Intrahepatic cholangiocarcinoma; TARE: Transarterial radioembolization; IMRT: Intensity-modulated radiation therapy.